Drug Profile
Mirikizumab - Eli Lilly and Company
Alternative Names: IL-23 antibody - Eli Lilly and Company; IL-23p19 antibody - Eli Lilly and Company; LY 3074828; Miri - Eli Lilly and Company; OMVOH; OmvohLatest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ulcerative colitis
- Phase III Crohn's disease
- Discontinued Plaque psoriasis
Most Recent Events
- 05 Feb 2024 Launched for Ulcerative colitis in United Kingdom (SC)
- 22 Nov 2023 Phase-III clinical trials in Ulcerative colitis (In adolescents, In children, Treatment-experienced) in Italy, Germany, France, Belgium, Australia, United Kingdom, Portugal, Poland, Netherlands, South Korea, Japan, Israel, Canada, USA (SC) (NCT05784246)
- 22 Nov 2023 Phase-III clinical trials in Ulcerative colitis (In adolescents, In children, Treatment-experienced) in USA, Canada, Israel, Japan, Netherlands, Poland, Portugal, United Kingdom, Australia, Belgium, France, Germany, Italy, South Korea (IV) (NCT05784246)